BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Research Notes

Target’s Revenue Has Shrunk for Three Straight Years. Its Stock Just Hit a 52-Week High.

Moe Alsumidaie by Moe Alsumidaie
August 14, 2026
in Research Notes
0
74
SHARES
1.2k
VIEWS
Share on XShare on LinkedInShare on Facebook

Target built its modern identity on a simple promise: the cheap-chic discount store where a family could grab groceries, a new lamp, and a pair of sneakers in one trip. For a while, that promise printed money. Then came 2022, when a pandemic-era inventory blunder left the company sitting on mountains of unsold goods, and margins collapsed. The years since have been a slow, grinding repair job, with each annual filing showing a business that earns less revenue than the year before but is slowly learning to keep more of what it does earn. Now the stock is back at its 52-week high, and the math and the mood are telling very different stories.

In one breath

Target’s fiscal year 2025 10-K shows revenue falling for a third consecutive year, down to $104.8 billion, while earnings per share slipped to $8.13. The stock trades at roughly 19 times earnings, above its own decade median, meaning the market is paying a premium-history price for a business still posting shrinking sales. The open question is whether the operational fixes now underway, new stores, remodeled formats, and a leadership change, can turn the revenue line before that premium runs out of patience.

Three years of less

The revenue arc is worth sitting with. Fiscal year 2022 was the peak at $109.1 billion. Every year since has been a step down, landing at $104.8 billion in the most recent full year. That is not a rounding error. It is roughly four billion dollars in annual sales that once existed and no longer do, more than Target earns in net income in a good year.

The cause matters as much as the number. The 2022 collapse was self-inflicted: Target over-ordered discretionary goods during the pandemic boom and then had to slash prices to clear shelves, crushing margins. The fiscal year 2024 10-K showed the margin repair in progress, with net margin recovering meaningfully from its trough. But fiscal year 2025 gave some of that back. A business earning three and a half cents on every dollar of sales has very little room for error.

BullScope TerminalTGT was the article. The engine is the product.Same yardsticks, any ticker: filed financials in, math-vs-mood out. Nothing here is advice; it is the evidence, organized.Run another company →

What the most recent quarter adds

The 10-Q for the quarter ended August 2, 2025 offered a mixed picture. Overall comparable sales, meaning sales at stores open at least a year, the standard retail measure of organic growth, fell nearly two percent. Digital comparable sales grew at a healthier clip, which sounds encouraging until you remember that digital is still the smaller piece of the business. The most recent quarterly filing available before today, the 10-Q for the quarter ended May 2, 2026, showed inventory cycling through the shelves less than twice a year, a pace that leaves capital sitting in stockrooms rather than working.

The 247 Wall St. earnings summary for Q2 fiscal 2026, covering the quarter ended August 2, 2026, reports revenue of $25.21 billion and a gross margin of 29.0%, but operating income fell nearly 20% year over year to $1.32 billion. Lower shrink, the industry term for theft and damaged goods, helped cushion the blow, but a drop of that size in operating income is a significant move in the wrong direction for a business already running on thin margins.

The leadership bet

The most consequential disclosure in the recent filings is not a number. It is the appointment of COO Michael Fiddelke as Target’s next CEO. Leadership transitions at large retailers carry real stakes: the person running the business sets the inventory philosophy, the capital allocation, and the pace of store investment. Target’s March 2026 strategic plan calls for more than 30 new stores and over 130 full remodels this year, alongside a projected $5 billion in capital expenditures. That is a large physical bet at a moment when the revenue line is still pointing down.

The balance sheet context matters here. Q1 2026 filings show total debt of $18.83 billion and a debt-to-EBITDA ratio of 2.4, meaning it would take roughly two and a half years of operating earnings to retire all the debt. That is manageable but not comfortable, especially with five billion dollars in annual capital spending and a free cash outflow in Q1. Bank of America analyst Chris Nardone, as reported by Benzinga in August 2026, raised his valuation estimate while expressing skepticism about whether the comparable sales improvement is durable, a cautious read on the durability of the recovery. Wolfe Research’s Spencer Hanus holds the opposite view, citing accelerated turnaround efforts. Both arguments are live, and the filed numbers do not yet resolve them.

Reading the numbers

  • Revenue, FY2025: $104.8 billion. What it is: total sales for the year ended January 31, 2026. What it means here: the third consecutive annual decline, down from a $109.1 billion peak. Everyday anchor: a household that once spent $109 at Target each week is now spending about $105. The direction matters more than the gap.
  • Net margin, FY2025: 3.5%. What it is: the share of each sales dollar left after every cost, tax, and interest payment. What it means here: margins recovered from a 2.5% trough but are slipping again. Everyday anchor: a coffee shop earning 3.5 cents on a $5 cup has almost no buffer if milk prices rise.
  • Operating income, Q2 FY2026: $1.32 billion, down ~20% year over year. What it is: profit from running the stores before interest and taxes. What it means here: the business is generating less from its core operations than a year ago, even as the stock price has risen. Everyday anchor: a landlord collecting less rent this year than last while asking a higher price for the building.
  • P/E ratio: 18.7 times, versus a decade median of 15.9 times (our data). What it is: the price tag per dollar of annual earnings, the multiple. What it means here: the market is paying more than its historical norm for a business with declining revenue and slipping margins. Everyday anchor: paying a premium for a restaurant that used to be busier.

The math, as filed, describes a business in repair mode: margins recovering but not yet stable, revenue still contracting, and capital being deployed aggressively into stores and technology. The mood, as priced, assumes the repair succeeds. Those two readings cannot both be right at the same time, and the Q2 2026 earnings report due August 19 is the next piece of evidence the market will use to decide which one to believe.

Sources

  • Target 10-K, fiscal year ended January 31, 2026 (SEC EDGAR)
  • Target 10-Q, quarter ended May 2, 2026 (SEC EDGAR)
  • Target 10-Q, quarter ended August 2, 2025 (SEC EDGAR)
  • Target 10-K, fiscal year ended February 1, 2025 (SEC EDGAR)
  • Target 10-K, fiscal year ended February 3, 2024 (SEC EDGAR)
  • 247 Wall St., Target Q2 2026 earnings summary
  • Target Corporation, March 2026 strategic plan press release
  • Target Corporation, Q1 2026 earnings press release
  • Benzinga, Bank of America analyst commentary, August 2026
BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.
BullScope TerminalYou just read TGT’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie

Moe Alsumidaie

Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.

Recommended For You

Arcutis: One Drug, Shrinking Losses, and a Label That Keeps Growing

by Moe Alsumidaie
October 23, 2026
0

For most of its life, Arcutis Biotherapeutics was a company with a single compelling bet: that a molecule called roflumilast, already proven in lung disease, could be reformulated...

Read moreDetails

One Drug, Nearly a Billion Dollars, and a Pipeline That Just Blinked

by Moe Alsumidaie
October 21, 2026
0

The short version Krystal Biotech built a profitable, cash-rich business on a single gene therapy approved just three years ago. The filed numbers show margins expanding sharply and...

Read moreDetails

Ardelyx: The Revenue Is Real, the Guidance Cut Is Realer

by Moe Alsumidaie
October 20, 2026
0

Three years ago, Ardelyx was burning through cash with almost nothing to show at the pharmacy counter. Then IBSRELA, its drug for irritable bowel syndrome with constipation, started...

Read moreDetails

Innoviva: The Royalties Are Shrinking. The Specialty Business Is Growing. Both Things Are True at Once.

by Moe Alsumidaie
October 20, 2026
0

Innoviva spent most of its life as a toll booth on two GSK inhalers. Every time a patient filled a BREO or ANORO prescription, Innoviva collected a royalty...

Read moreDetails

One Drug Is Carrying the Weight. Two Acquisitions Just Added More.

by Moe Alsumidaie
October 19, 2026
0

Three years ago, Tarsus Pharmaceuticals was shrinking. Revenue had fallen by more than half in 2022, then fell again in 2023, and the company was burning through cash...

Read moreDetails
Next Post

Evidence Sheet: Bank Of America Corp /de/ (BAC)

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

NVIDIA at the cheap end of its own decade: when the math outgrows the mood

NVIDIA at the cheap end of its own decade: when the math outgrows the mood

July 30, 2026

Target’s Revenue Has Shrunk for Three Straight Years. Its Stock Just Hit a 52-Week High.

August 14, 2026

Caterpillar renews three-year credit facility with unchanged $4 billion commitment as borrowing costs shift to SOFR

September 24, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.